Known hypersensitivity to nitazoxanide;

History of cardiomyopathies, hepatopathies, or nephropathies;

Antineoplastic treatment with chemotherapy or radiotherapy;

Severe autoimmune diseases with immunosuppression;

Transplant recipients;

Any uncompensated systemic disease at the investigator's discretion;

Participation in clinical studies in the last 12 months;

Pregnant or breastfeeding individuals;

Suspected bacterial coinfection or prescription of antibiotic therapy at enrollment;

Diagnosis of neurological disease (traumatic brain injury, stroke, Parkinson's disease, Alzheimer's disease, other dementias);

Diagnosis of developmental disorder (ADHD, ASD, learning disabilities, intellectual disability, Rett syndrome);

Significant hearing or vision impairment.

Efficacy and Safety of Nitazoxanide 600 Mg in the Outpatient Treatment of COVID-19 and Influenza